scholarly journals Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis

Cell Reports ◽  
2020 ◽  
Vol 33 (10) ◽  
pp. 108473
Author(s):  
Huihui Fan ◽  
Huda I. Atiya ◽  
Yeh Wang ◽  
Thomas R. Pisanic ◽  
Tza-Huei Wang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Epigenomic Reprogramming ◽  
Mesenchymal Epithelial Transition

scholarly journals Mesenchymal Stem Cells As Guideposts for Nanoparticle-Mediated Targeted Drug Delivery in Ovarian Cancer

Cancers ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 965
Author(s):  
Buddhadev Layek ◽  
Mihir Shetty ◽  
Susheel Kumar Nethi ◽  
Drishti Sehgal ◽  
Timothy K. Starr ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Delivery ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Solid Tumors ◽  
Efficient Delivery ◽  
Tumor Tissues ◽  
Specific Accumulation ◽  
Targeting Strategy ◽  
High Binding Affinity

Nanocarriers have been extensively utilized for the systemic targeting of various solid tumors and their metastases. However, current drug delivery systems, in general, suffer from a lack of selectivity for tumor cells. Here, we develop a novel two-step targeting strategy that relies on the selective accumulation of targetable synthetic receptors (i.e., azide moieties) in tumor tissues, followed by delivery of drug-loaded nanoparticles having a high binding affinity for these receptors. Mesenchymal stem cells (MSCs) were used as vehicles for the tumor-specific accumulation of azide moieties, while dibenzyl cyclooctyne (DBCO) was used as the targeting ligand. Biodistribution and antitumor efficacy studies were performed in both orthotopic metastatic and patient-derived xenograft (PDX) tumor models of ovarian cancer. Our studies show that nanoparticles are retained in tumors at a significantly higher concentration in mice that received azide-labeled MSCs (MSC-Az). Furthermore, we observed significantly reduced tumor growth (p < 0.05) and improved survival in mice receiving MSC-Az along with paclitaxel-loaded DBCO-functionalized nanoparticles compared to controls. These studies demonstrate the feasibility of a two-step targeting strategy for efficient delivery of concentrated chemotherapy for treating solid tumors.

scholarly journals Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer

PLoS ONE ◽  
2017 ◽  
Vol 12 (12) ◽  
pp. e0190125 ◽  
Author(s):  
Lindsay M. Kuroki ◽  
Xingjian Jin ◽  
Igor P. Dmitriev ◽  
Elena A. Kashentseva ◽  
Matthew A. Powell ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Human Mesenchymal Stem Cells ◽  
Transduction Efficiency

scholarly journals Antitumor Activities of Human Placenta-Derived Mesenchymal Stem Cells Expressing Endostatin on Ovarian Cancer

PLoS ONE ◽  
2012 ◽  
Vol 7 (7) ◽  
pp. e39119 ◽  
Author(s):  
Lan Zheng ◽  
Dongmei Zhang ◽  
Xiancheng Chen ◽  
Li Yang ◽  
Yuquan Wei ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Human Placenta ◽  
Antitumor Activities

168 Mesenchymal stem cells protects ovarian cancer cells from chemotherapy through IL6 secretion

2015 ◽  
Vol 51 ◽  
pp. S19-S20
Author(s):  
M. Gosset ◽  
C. Geyl ◽  
M. Mirshahi ◽  
M. Maleki ◽  
A. Rafii ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cancer Cells ◽  
Ovarian Cancer Cells
Sign in / Sign up

Export Citation Format

Share Document